Systematic Financial Management LP trimmed its holdings in shares of CVS Health Corp (NYSE:CVS) by 5.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,055 shares of the pharmacy operator’s stock after selling 1,624 shares during the quarter. Systematic Financial Management LP’s holdings in CVS Health were worth $2,119,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of CVS. Pacer Advisors Inc. lifted its position in shares of CVS Health by 7.8% during the 3rd quarter. Pacer Advisors Inc. now owns 35,097 shares of the pharmacy operator’s stock valued at $2,854,000 after acquiring an additional 2,543 shares during the period. Exencial Wealth Advisors LLC lifted its position in shares of CVS Health by 36.1% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 43,147 shares of the pharmacy operator’s stock valued at $3,509,000 after acquiring an additional 11,436 shares during the period. Girard Partners LTD. lifted its position in shares of CVS Health by 2.7% during the 3rd quarter. Girard Partners LTD. now owns 66,690 shares of the pharmacy operator’s stock valued at $5,423,000 after acquiring an additional 1,775 shares during the period. Thompson Siegel & Walmsley LLC lifted its position in shares of CVS Health by 16.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 122,422 shares of the pharmacy operator’s stock valued at $9,955,000 after acquiring an additional 17,475 shares during the period. Finally, Waldron LP lifted its position in shares of CVS Health by 22.5% during the 3rd quarter. Waldron LP now owns 4,488 shares of the pharmacy operator’s stock valued at $364,000 after acquiring an additional 825 shares during the period. 81.70% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on the stock. Cowen reiterated an “outperform” rating and set a $99.00 target price (up previously from $81.00) on shares of CVS Health in a research report on Thursday, January 18th. Vetr downgraded shares of CVS Health from a “hold” rating to a “sell” rating and set a $76.66 target price on the stock. in a research report on Tuesday, January 16th. Leerink Swann boosted their target price on shares of CVS Health from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Monday, January 8th. Oppenheimer reiterated a “buy” rating and set a $95.00 target price on shares of CVS Health in a research report on Monday, October 9th. Finally, Mizuho set a $90.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. CVS Health has an average rating of “Buy” and an average target price of $87.25.
Shares of CVS Health Corp (NYSE:CVS) opened at $80.95 on Tuesday. CVS Health Corp has a one year low of $66.45 and a one year high of $84.00. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market cap of $82,000.00, a price-to-earnings ratio of 16.73, a PEG ratio of 1.26 and a beta of 0.90.
CVS Health (NYSE:CVS) last posted its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. During the same quarter in the prior year, the business posted $1.64 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. research analysts expect that CVS Health Corp will post 5.89 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be paid a $0.50 dividend. The ex-dividend date is Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.47%. CVS Health’s payout ratio is 41.32%.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.61% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.